Isocromosoma Filadelfia en dos pacientes con leucemia mieloide crónica

Lavaut Sánchez, Kalia; Quintero Sierra, Yamile; Hernández Aguilar, Norbelys.
Rev. cuba. hematol. inmunol. hemoter ; 35(1): e960, ene.-mar. 2019. graf
Artigo em Espanhol | LILACS | ID: biblio-1003890

Documentos relacionados

  1. Asymptomatic chronic-phase chronic myeloid leukemia BCR-ABL. (+) without splenomegaly: A case report.
  2. Successful kidney transplantation in a patient with pre-existing chronic myeloid leukemia treated with imatinib.
  3. Chronic Myeloid Leukemia in a Patient with Previous Idiopathic Thrombocytopenic Purpura: How to Manage Imatinib Together with Eltrombopag.
  4. Reversal of Glanzmann thrombasthenia platelet phenotype after imatinib treatment in a pediatric chronic myeloid leukemia patient.
  5. Tyrosine Kinase Inhibitor Therapies in Chronic Myeloid Leukemia: Effects on Clinical Characteristics and Triglyceride-to-High Density Lipoprotein Cholesterol Ratio.
  6. Clinical outcomes of second-generation tyrosine kinase inhibitors versus imatinib in older patients with CML.
  7. A single-cell atlas identifies pretreatment features of primary imatinib resistance in chronic myeloid leukemia.
  8. <i>MDR1</i> gene polymorphisms and imatinib response in chronic myeloid leukemia: A meta-analysis.
  9. Late relapse of chronic myeloid leukemia after allogeneic bone marrow transplantation points to KANSARL (KANSL1::ARL17A) alteration: a case report with insights on the molecular landscape.
  10. DIA-Based Proteomics Identifies IDH2 as a Targetable Regulator of Acquired Drug Resistance in Chronic Myeloid Leukemia.